| Computational oncology—mathematical modelling of drug regimens for precision medicine D Barbolosi, J Ciccolini, B Lacarelle, F Barlési, N André Nature reviews Clinical oncology 13 (4), 242-254, 2016 | 218 | 2016 |
| Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients C Solas, A Lafeuillade, P Halfon, S Chadapaud, G Hittinger, B Lacarelle Antimicrobial agents and chemotherapy 47 (1), 238-243, 2003 | 216 | 2003 |
| Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. J Albanese, C Martin, B Lacarelle, P Saux, A Durand, F Gouin Anesthesiology 73 (2), 214-217, 1990 | 161 | 1990 |
| Pharmacogenetics of capecitabine in advanced breast cancer patients R Largillier, MC Etienne-Grimaldi, JL Formento, J Ciccolini, JF Nebbia, ... Clinical cancer research 12 (18), 5496-5502, 2006 | 145 | 2006 |
| First results on ProtoDUNE-SP liquid argon time projection chamber performance from a beam test at the CERN Neutrino Platform B Abi, AA Abud, R Acciarri, MA Acero, G Adamov, M Adamowski, ... Journal of Instrumentation 15 (12), P12004, 2020 | 135 | 2020 |
| A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy J Ciccolini, C Mercier, A Evrard, L Dahan, JC Boyer, F Duffaud, K Richard, ... Therapeutic drug monitoring 28 (5), 678-685, 2006 | 118 | 2006 |
| Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil–related severe toxicities: hype or hope? J Ciccolini, E Gross, L Dahan, B Lacarelle, C Mercier Clinical colorectal cancer 9 (4), 224-228, 2010 | 116 | 2010 |
| A simple and rapid high‐performance liquid chromatographic (HPLC) method for 5‐fluorouracil (5‐FU) assay in plasma and possible detection of patients with impaired … J Ciccolini, C Mercier, MF Blachon, R Favre, A Durand, B Lacarelle Journal of clinical pharmacy and therapeutics 29 (4), 307-315, 2004 | 106 | 2004 |
| Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations A Lafeuillade, C Solas, P Halfon, S Chadapaud, G Hittinger, B Lacarelle HIV clinical trials 3 (1), 27-35, 2002 | 106 | 2002 |
| Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites E Seree, PH Villard, JM Pascussi, T Pineau, P Maurel, QB Nguyen, ... Gastroenterology 127 (5), 1436-1445, 2004 | 104 | 2004 |
| DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity CG Yang, J Ciccolini, A Blesius, L Dahan, D Bagarry-Liegey, C Brunet, ... Cancer chemotherapy and pharmacology 67, 49-56, 2011 | 100 | 2011 |
| Thawed human hepatocytes in primary culture M Dou, G De Sousa, B Lacarelle, M Placidi, PL de La Porte, M Domingo, ... Cryobiology 29 (4), 454-469, 1992 | 99 | 1992 |
| Effects of Tobacco Smoke on the Gene Expression of theCyp1a, Cyp2b, Cyp2e, andCyp3aSubfamilies in Mouse Liver and Lung: Relation to Single Strand Breaks of DNA PH Villard, EM Seree, JL Re, M De Meo, Y Barra, L Attolini, G Dumenil, ... Toxicology and applied pharmacology 148 (2), 195-204, 1998 | 94 | 1998 |
| Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs C Le Guellec, B Lacarelle, PH Villard, H Point, J Catalin, A Durand Anesthesia & Analgesia 81 (4), 855-861, 1995 | 94 | 1995 |
| Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine S Benzekry, E Pasquier, D Barbolosi, B Lacarelle, F Barlési, N André, ... Seminars in Cancer Biology 35, 53-61, 2015 | 88 | 2015 |
| Effect of cigarette smoke on UDP‐glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice PH Villard, R Hcrber, EM Sérée, L Attolini, J Magdalou, B Lacarelle Pharmacology & toxicology 82 (2), 74-79, 1998 | 83 | 1998 |
| Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration I Poizot-Martin, C Solas, J Allemand, V Obry-Roguet, V Pradel, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (4), 375-380, 2013 | 81 | 2013 |
| Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A M Gantenbein, L Attolini, B Bruguerolle, PH Villard, F Puyoou, A Durand, ... Drug metabolism and disposition 28 (4), 383-385, 2000 | 79 | 2000 |
| Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines R Grepin, M Guyot, M Jacquin, J Durivault, E Chamorey, A Sudaka, ... Oncogene 31 (13), 1683-1694, 2012 | 77 | 2012 |
| Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. TF Woolf, WF Pool, SM Bjorge, T Chang, OP Goel, CF Purchase, ... Drug metabolism and disposition 21 (5), 874-882, 1993 | 77 | 1993 |
